CHRYSALIS Study Shows Potential of Amivantamab/Lazertinib in EGFRm NSCLC
September 5th 2023Se-Hoon Lee, MD, an oncologist at the Samsung Medical Center in Seoul, Korea, discusses his focus of research in the lung cancer space, including the phase 1 CHRYSALIS study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Watch
Trials Investigate Sacituzumab as Earlier Treatment for Breast Cancer
September 3rd 2023Sara Tolaney, MD, MPH, discusses key takeaways from the TROPiCS-02 study of sacituzumab govitecan-hziy for patients with hormone receptor-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.
Watch